 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the companys common stock to one new employee as an inducement award under the companys 2019 Inducement Plan. The grant was made in accordance with Nasdaq Listing Rule 5635c4. The stoc 